Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Rituximab Plus Vincristine Sulfate Liposomes Injection in the Treatment of Relapsed or Refractory Aggressive Non Hodgkin's Lymphoma
Conditions
Interventions
Vincristine Sulfate Liposome Injection plus rituximab
Locations
2
United States
University of California
San Francisco, California, United States
Leeds General Infirmary
Leeds, West Yorkshire, United Kingdom
Start Date
September 1, 2001
Primary Completion Date
April 1, 2004
Completion Date
April 1, 2005
Last Updated
January 3, 2020
NCT05529069
NCT06263491
NCT05139017
NCT05006716
NCT06026319
NCT03523975
Lead Sponsor
Acrotech Biopharma Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions